Study on Metformin’s Cardioprotective Effects in Type 1 Diabetes

Background on Diabetes and Cardiovascular Disease

A recent study published in the International Journal of Molecular Sciences explored the cardioprotective effects of metformin in individuals with type 1 diabetes and heart disease. Research indicates that patients with diabetes mellitus face a two to four-fold increased risk of developing cardiovascular disease (CVD). Diabetes mellitus is a chronic condition characterized by elevated blood sugar levels and can be categorized into three types: type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes.

Understanding Metformin and Its Role

Metformin has demonstrated protective effects on blood vessels. Type 1 diabetes, also known as juvenile-onset diabetes, occurs when the body fails to produce insulin effectively, a hormone crucial for maintaining sugar balance. In contrast, patients with type 2 diabetes often produce adequate insulin but experience insulin resistance, hindering the hormone’s functionality. Treatment for type 1 diabetes typically involves insulin therapy, while metformin is commonly prescribed for type 2 diabetes. Metformin exhibits anti-hyperglycemic and lipid-lowering effects, along with vasculoprotective properties. However, the precise mechanisms through which metformin operates remain poorly understood and require further investigation.

MERIT Study Overview

The recent MERIT study, conducted by Ahmed and colleagues, investigated the protective role of metformin in type 1 diabetes, specifically its impact on four microRNAs. MicroRNAs (miRs) are small, single-stranded non-coding RNAs that silence genes by promoting messenger RNA degradation or inhibiting their translation into functional proteins. The researchers focused on miR-222, miR-195, miR-21a, and miR-126 due to their significant associations with CVD identified in previous studies.

Study Design and Findings

In the study, individuals with type 1 diabetes were divided into two groups: a treatment group receiving metformin and a standard group receiving regular insulin therapy. Additionally, 23 age and gender-matched participants without diabetes or CVD were included for comparison.

The MERIT study yielded notable results, indicating that individuals with well-controlled type 1 diabetes and no CVD had significantly higher levels of plasma miRs at the study’s onset. After an eight-week treatment period with metformin, patients exhibited significantly lower levels of miR-195, miR-21a, and miR-222, while miR-126 levels remained unchanged.

Implications of MicroRNA Levels

All four microRNAs examined have been associated with vascular health. Specifically, previous research has linked elevated miR-21a levels to vascular damage and adverse health outcomes in diabetic patients. Another study indicated that reduced plasma miR-222 levels correlate with diminished circulating endothelial cell levels, which serve as markers for endothelial injury.

Conclusion

The findings from the MERIT study suggest that the cardioprotective effects of metformin may be, in part, mediated by its ability to lower levels of anti-angiogenic microRNAs and enhance vascular function in diabetic individuals.

Reference

Ahmed, F., Bakhashab, S., Bastaman, I., Crossland, R., Glanville, M., & Weaver, J. (2018). Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study. International Journal of Molecular Sciences, 19(10), 3242.